x

¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2015

1,267
© Thomson Reuters, Journal Citation Reports, 2015

Indexada en:

Current Contents/Clinical Medicine, Journal Citation Reports, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, MEDES, PASCAL, SCOPUS, ScienceDirect

Métricas

  • Factor de Impacto: 1,267(2015)
  • 5-años Factor de Impacto: 1,344
  • SCImago Journal Rank (SJR):0,22
  • Source Normalized Impact per Paper (SNIP):0,385
doi: 10.1016/S0025-7753(05)72185-0
Originales
Proteína C reactiva en la fase aguda del ictus
C-reactive protein in the acute phase of ischemic stroke
José Carlos Arévalo-Lorido, , Juana Carretero-Gómez, José María Calvo- Romero, Jorge Manuel Romero-Requena, Juan Luis Pérez-Alonso, Concepción Gutiérrez-Montaño, Carmen Ortiz-Descane
Servicio de Medicina Interna. Hospital Comarcal de Zafra. Zafra. Badajoz. España
Recibido 22 marzo 2004, Aceptado 07 junio 2005
Resumen
Fundamento y objetivo

Valorar si los valores de proteína C reactiva (PCR) son de utilidad para definir el pronóstico de los pacientes con enfermedad cerebrovascular en fase aguda.

Pacientes y método

Se ha estudiado a 117 sujetos con enfermedad cerebrovascular en fase aguda, a los que se realizaron determinaciones de PCR en las primeras 48 h tras el episodio, así como perfil lipídico y otras determinaciones hematológicas, junto con tomografía computarizada o resonancia magnética craneales. Se valoró a los pacientes mediante escalas de capacidad funcional y deterioro neurológico y se les clasificó en 3 grupos atendiendo al pronóstico clínico y funcional durante el ingreso (ataque isquémico transitorio, ictus favorables e ictus desfavorables).

Resultados

Un total de 32 pacientes se clasificó como ataque isquémico transitorio, 31 como ictus favorables y 54 como ictus desfavorables. Cada grupo mostró menor capacidad functional (p<0,005) y mayor deterioro neurológico (p<0,0001) a medida que empeoraba el pronóstico. La media de la PCR en cada grupo fue de 1,7, 1,07 y 3,6mg/dl, respectivamente (p<0,0001).

Conclusiones

En nuestra muestra existen diferencias significativas en los valores de PCR entre los grupos con mejor y peor pronóstico que se relacionan con el grado de deterioro neurológico, capacidad funcional y extensión radiológica de la lesión principalmente cuando dichos valores medios (desviación estándar) son superiores a 3,6 (0,49) mg/dl.

Resumen
Background and objective

We aimed to assess the prognostic importance of C-reactive protein (CRP) in the acute phase of ischemic stroke in-patients.

Patients and method

One hundred and seventeen patients within 48h after index ischemic stroke were included. CRP levels and blood samples were obtained at this time, and a brain computerized tomography or magnetic resonance imaging were performed. Neurological and functional disability were evaluated and patients were divided according to the outcome into the following categories: transient ischemic attack, favorable stroke, and non-favorable stroke.

Results

32 in-patients were classified as transient ischemic attack, 31 as favourable stroke, and 54 as non-favorable stroke. There was a worsening in neurological (p<0.0001) and functional (p<0.005) disabilities from the TIA group to non-favorable stroke. The CRP mean, by category, was 1.7, 1.07 and 3.6mg/dl, respectively (p<0.0001).

Conclusions

We found increased levels of CRP in the non-favorable stroke category, that was related with neurological and functional disabilities, and with radiological findings, mainly when levels were greater than 3.6 (0.49) mg/dl.

Palabras clave
Proteína C reactiva, Accidente cerebrovascular, Enfermedad cerebrovascular
Key words
C-reactive protein, Ischemic accident, Ischemic stroke
El Texto completo solo esta disponible en PDF
Referencias bibliográficas
1.
V. Bodi,J. Sanchis,A. Llacer,L. Facila,J. Núñez,M. Pellicer
Valor independiente de la proteína C reactiva para predecir acontecimientos mayores al primer mes y al año en los syndromes coronarios agudos sin elevación del ST
Med Clin (Barc), 122 (2004), pp. 248-252
2.
P.M. Ridker,J.E. Buring,J. Shih,M. Matias,C.H. Hennekens
Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
Circulation, 98 (1998), pp. 731-733
3.
P.M. Ridker,M. Cushman,M.J. Stampfer,R.P. Tracy,C.H. Hennekens
Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men
N Engl J Med, 336 (1997), pp. 973-979
4.
S. Verma,P. Szmitko,E. Yeh
C-reactive protein. Structure affects function
Circulation, 109 (2004), pp. 1914-1917
5.
P.M. Ridker,N. Rifai,L. Rose,J.E. Buring,N.R. Cook
Comparison of C-reactive protein and lowdensity lipoprotein cholesterol levels in the prediction of first cardiovascular events
N Engl J Med, 347 (2002), pp. 1557-1565
6.
N.S. Rost,P.A. Wolf,C.S. Kase,M. Kelly-Hayes,H. Silbershatz,J.M. Massaro
Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham Study
Stroke, 32 (2001), pp. 2575-2579
7.
M. Di Napoli,F. Papa,V. Bocola
C-reactive protein in ischemic stroke. An independent prognostic factor
Stroke, 32 (2001), pp. 917-924
8.
K. Winbeck,H. Poppert,T. Etgen,B. Conrad,D. Sander
Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke
Stroke, 33 (2002), pp. 2459-2464
9.
P.D. Lyden,M. Lu,S.R. Levine,T.G. Brott,J. Broderick,For the NINDS rtPA Stroke Study Group
A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity
Stroke, 32 (2001), pp. 1310-1317
10.
F.I. Mahoney,D.W. Barthel
Functional evaluation: the Barthel Index
Md State Med J, 14 (1965), pp. 61-65
11.
W. Hacke,M. Kaste,C. Fieschi,R. Von Kummer,A. Davalos,D. Meier,For the second European- Australasian Acute Stroke Study Investigators
Randomised double-blind placebo-controlled trial of thrombolitic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
Lancet, 352 (1998), pp. 1245-1251
12.
S.J. Pocock,V. McCormack,F. Gueyffier,F. Boutilie,R.H. Fagard,J.P. Boissel
A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials
BMJ, 323 (2001), pp. 75-81
13.
Ivename Expert Panel on Detection, Evaluation and Treatment of High blood cholesterol in adults. Collective name. Executive summary of the Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of high blodd Cholesterol in adults (Adults Treatment Panel III). JAMA. 2001;285:2486-97.
14.
1999 World Health Organization
International Society of Hypertension. Guidelines for management of hypertension
J Hypertens, 89 (1999), pp. 1329-1445
15.
P.M. Ridker,P.W.F. Wilson,S.M. Grundy
Should Creactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
Circulation, 109 (2004), pp. 2818-2825
Correspondencia: Dr. J.C. Arévalo-Lorido. Servicio de Medicina Interna. Hospital Comarcal de Zafra. Ctra. Badajoz-Granada, s/n. 06300 Zafra. Badajoz. España.
Copyright © 2005. Elsevier España S.L.